Matthew Mahady

A collection of cancer statistics and facts

Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) Genentech: Continues to Grow Oncology Portfolio 2) ImClone: Erbitux News Initially Raise ImClone Shares 3) AstraZeneca: Prostate Drug Enters Phase II 4) Kiadis Pharma: One Blood Cancer Treatment Clears Phase II Hurdles, Another May Hit Market By 2009 5) Big Pharma Stocks Show Signs of Life

An oral therapy currently utilized in the treatment of advanced kidney cancer may be on the threshold of obtaining a major new indication.

New data recently published in the Journal of Clinical Oncology has provided a degree of hopeful news to oncologists and their patients, suggesting that progress is being made in the fight against cancer and that a number of trends are pointing toward continued gains.

Physicians' Financial News focuses on newsmaking and/or notable companies in the oncology/biotech sector. In this issue: 1) Pharmion: Oncology-Centered Focus Fuels Continued Pharmion Growth 2) Bristol-Myers Squibb: Treatment-Resistant Breast Cancer Targeted 3) Merger-Mania Poised to Envelop Biotech Sector? 4) GlaxoSmithKline: Oral Therapy Option Offered for Small-Cell Lung Cancer Relapse 5) Immunomedics,Inc.: Immunomedics Wins Pancreatic Cancer Patent 6) ZymoGenetics: Promising Kidney Cancer Therapy Moves Toward Phase II

A collection of statistics and facts on skin cancer and melanoma

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector.

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue:Millennium Pharmiceuticals, Inc.: Future Looking Bright After Record

A collection of cancer statistics and facts.

Physicians' Financial News focuses on news-making and/or notable companies in the oncology biotechnology sector. I

Physicians' Financial News focuses on news-making and/or notable companies in the oncology biotechnology sector.

Physicians' Financial News focuses on news-making and/or notable companies in the oncology biotechnology sector. In this issue: Onyx Pharmaceuticals, Inc.: Flourishing on Strength of Single Agent With Multiple Applications Cephalon, Inc.: Chronic Lymphocytic Leukemia Treatment Approved: First New Option in Seven Years Non-Hodgkin's Lymphoma: New Challenges, New Hope Sunesis Pharmaceuticals, Inc.: Potential Ovarian Cancer Treatment Advancing Through Development Pipeline BioNumerik Pharmaceuticals, Inc. and ASKA Pharmaceutical: Enhanced Survival, Tolerability Observed in Joint Non-Small Cell Lung Cancer Trial

When ASCO decision-makers decided to revise the manner in whichthey disseminate eagerly anticipated clinical research data, the news made headlines and reverberations that were felt throughout the worlds of oncology research, practice, finance, and investment.

Academic research is fueling tremendous strides in oncology and biotechnology. The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

Scientists at the Dana-Farber Cancer Institute, Boston, Massachusetts, have linked the CDK8 gene to colon cancer, a previously unsuspected association.

University of Pittsburgh scientists ecently discovered a virus that they have determined is the cause of Merkel cell carcinoma.

Stanford University School of Medicine investigators may have discovered a new chemotherapy target for a deadly form of leukemia. A molecular signal, glycogen synthase kinase 3 (GSK3), known to regulate cell growth appears to play a "double agent" role.

Researchers at the Johns Hopkins University School of Medicine in Baltimore, Maryland, have developed an innovative test to screen for chemical modifications to DNA, which are known as methylation. The test could potentially be used to diagnose cancer early on and to assess patients' response to cancer therapies.

Researchers at the Medical College of Wisconsin in Milwaukee have announced a pending patent on a new synthetic version of a protein involved in some cancers and immune system diseases.

In what researchers are touting as a first-of-its-kind finding, Houston-based University of Texas M. D. Anderson Cancer Center investigators have discovered a potential connection between exposure to the hepatitis B virus and an increased risk of developing pancreatic cancer.

Merck has won FDA approval to market Gardasil,which immunizes patients against cancer-causing strains of the human papillomavirus (HPV), as a preventive vaccine for vaginal and vulvar cancers, as well.

Eli Lilly and Company has obtained FDA approval for an expanded indication of its anti-cancer agent Alimta. This new indication allows Alimta to be combined with cisplatin as a first-line treatment in locally advanced or metastatic non–small cell lung cancer (NSCLC) for patients with nonsquamous histology.

At the 33rd Annual ESMO Congress in Stockholm, Sweden, investigators presented new data from 3 clinical trials that indicate Zometa reduces the risk of local and distant breast cancer recurrence in pre- and postmenopausal women with early stage disease (stage I or II).

MediGene, based in Germany, has a new product in late-stage development that may offer hope to patients with inoperable pancreatic cancer.

ProStrakan Group plc, announced it had attained FDA approval to market Sancuso in the United States. The company describes Sancuso as the first and only anti-nausea and vomiting agent formulated for delivery via a transdermal patch, designed specifically to prevent these adverse effects in patients with cancer who are undergoing chemotherapy.